Comencemos

Hay varias opciones que pueden ayudarle a cubrir los gastos de su medicamento de Genentech. Responda a estas preguntas sencillas para averiguar cuál puede ser la adecuada para usted.

  • ¿Tiene seguro médico?

  • ¿Tiene seguro médico comercial?

    ¿Qué significa esto?
  • ¿Está recibiendo alguna ayuda económica para poder pagar el medicamento?

    ¿Qué significa esto?
  • ¿Toma Esbriet para un uso aprobado por la FDA?

Puede que Reúna los Requisitos para que se le Derive al Programa de Copago de HEMLIBRA

HEMLIBRA Access Solutions puede derivarle al Programa de Copago de HEMLIBRA. Si reúne los requisitos, puede ayudarle con los costos del bolsillo de su medicamento de Genentech.*

 

Más Información

 

*Para poder optar al Programa de Copago de HEMLIBRA, el paciente debe disponer de un seguro comercial, no debe tener Medicare, Medicaid ni ningún otro seguro público y debe cumplir otros criterios de elegibilidad. También debe aceptar las reglas establecidas en los términos y condiciones del programa. Visite HEMLIBRACopay.com para ver la lista completa de términos y condiciones.

Puede que Reúna los Requisitos para que se le Derive a una Fundación Independiente de Asistencia al Copago

Si necesita ayuda con el copago de su medicamento de Genentech, podemos derivarle a una fundación independiente de asistencia al copago.*

 

Más Información

 

*Las fundaciones independientes de asistencia al copago tienen sus propias normas para la elegibilidad. No podemos garantizarle que una fundación le vaya a ayudar. Solo podemos derivarle para que esta le asista con su estado de salud. No respaldamos ni mostramos preferencia económica por ninguna fundación en particular. Las fundaciones a las que le derivemos no son las únicas que pueden ayudarle.

Puede que Reúna los Requisitos para que se le Derive a la fundación Genentech® Access to Care Foundation, o GATCF

La GATCF puede ayudarle a conseguir su medicamento de Genentech de forma gratuita si cumple los requisitos.*

 

Más Información

 

*Si cuenta con un seguro médico, primero debe haber probado otros tipos de asistencia a pacientes para ser apto para recibir medicamentos gratis de Genentech a través de la GATCF. Esto incluye el Programa de Copago de HEMLIBRA y la ayuda de fundaciones independientes de asistencia al copago. También debe cumplir otros criterios financieros. Si no tiene seguro, debe cumplir unos criterios financieros diferentes.

Important Safety Information & Indication

What it Treats

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors.

Important Safety Information

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Discontinue prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent, and the dose and schedule you should use. HEMLIBRA may cause the following serious side effects when used with aPCC (FEIBA®), including:

  • Thrombotic microangiopathy (TMA). This is a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs. Get medical help right away if you have any of the following signs or symptoms during or after treatment with HEMLIBRA:
    • confusion
    • weakness
    • swelling of arms and legs
    • yellowing of skin and eyes
    • stomach (abdomen) or back pain
    • nausea or vomiting
    • feeling sick
    • decreased urination
  • Blood clots (thrombotic events). Blood clots may form in blood vessels in your arm, leg, lung or head. Get medical help right away if you have any of these signs or symptoms of blood clots during or after treatment with HEMLIBRA:
    • swelling in arms or legs
    • pain or redness in your arms or legs
    • shortness of breath
    • chest pain or tightness
    • fast heart rate
    • cough up blood
    • feel faint
    • headache
    • numbness in your face
    • eye pain or swelling
    • trouble seeing

If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

Before using HEMLIBRA, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or plan to become pregnant. It is not known if HEMLIBRA may harm your unborn baby. Females who are able to become pregnant should use birth control (contraception) during treatment with HEMLIBRA.
  • are breastfeeding or plan to breastfeed. It is not known if HEMLIBRA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use HEMLIBRA?

See the detailed “Instructions for Use” that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

What are the other possible side effects of HEMLIBRA?

The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain.

These are not all of the possible side effects of HEMLIBRA. Call your doctor for medical advice about side effects.

General information about the safe and effective use of HEMLIBRA.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HEMLIBRA for a condition for which it was not prescribed. Do not give HEMLIBRA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about HEMLIBRA that is written for health professionals.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the HEMLIBRA full Prescribing Information and Medication Guide for more important safety information including Serious Side Effects.